Emerging opportunities include advancements in mRNA and viral vector technologies for rapid development, improved distribution through digital tracking, and public-private partnerships enhancing ...

Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in ...

The Trump administration’s decision to halt nearly $500 million for mRNA vaccine research has made investors more hesitant to ...

Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on ...

Canceling federal mRNA vaccine projects threatens much more than pandemic response, according to Michigan State University’s ...

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

HealthSecretary Robert F. Kennedy Jr. has defunded research in messenger RNA vaccines, which could jeopardize efforts to ...

The director of the National Institutes of Health, Jay Bhattacharya, explained why the federal government wound up $500 ...

A detailed picture of what happens when DNA transcription is paused early in the process has been obtained by structural ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

TOKYO -- Japanese biotechnology company PrimRNA will launch clinical trials for a treatment using messenger RNA to repair osteoarthritis of the knee, a condition that afflicts many older adults.